02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:44 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
17:57 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
11:00 , Nov 7, 2018 |  BC Extra  |  Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
17:27 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Foamix's minocycline foam meets in third Phase III for acne

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) reported on Sept. 11 that FMX101 met the co-primary endpoints in the Phase III FX2017-22 trial to treat moderate to severe acne. By year end, the company plans to submit an...
13:20 , Sep 14, 2018 |  BC Extra  |  Financial News

Foamix raises $70M following Phase III acne readout

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) raised $70 million through the sale of 11.7 million shares at $6 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. The price is a tiny discount...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:47 , Jul 5, 2017 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....